Novartis Ag (NVS) FCF Margin Growth (3y) (2012 - 2025)
Novartis Ag (NVS) FCF Margin Growth (3y) (2012 - 2025) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
FCF Margin Growth (3y) (Qtr) |
| 1 |
Eli Lilly |
1,066.16 Bn |
1,060.88 Bn |
16.22 Bn |
-7.00 |
| 2 |
Johnson & Johnson |
611.69 Bn |
589.64 Bn |
15.96 Bn |
-537.00 |
| 3 |
AbbVie |
444.34 Bn |
434.99 Bn |
10.78 Bn |
-911.00 |
| 4 |
Astrazeneca |
284.94 Bn |
277.05 Bn |
12.61 Bn |
146.00 |
| 5 |
Merck |
224.23 Bn |
218.58 Bn |
12.09 Bn |
1,568.00 |
| 6 |
Amgen |
195.12 Bn |
183.08 Bn |
5.87 Bn |
534.00 |
| 7 |
Gilead Sciences |
156.45 Bn |
148.73 Bn |
5.52 Bn |
913.00 |
| 8 |
Pfizer |
136.01 Bn |
123.24 Bn |
-1.21 Bn |
9,115.00 |
| 9 |
Novartis Ag |
113.45 Bn |
113.67 Bn |
- |
- |
| 10 |
Biogen |
30.87 Bn |
26.59 Bn |
1.82 Bn |
820.00 |
| Date | Value |
|---|
| Jun 30, 2025 |
1,838.00 |
| Dec 31, 2024 |
513.00 |
| Jun 30, 2024 |
667.00 |
| Dec 31, 2023 |
-286,549.00 |
| Jun 30, 2023 |
-377.00 |
| Jun 30, 2022 |
257.00 |
| Dec 31, 2021 |
-16,824.00 |
| Jun 30, 2021 |
246.00 |
| Mar 31, 2021 |
-3,415.00 |
| Dec 31, 2020 |
289,455.00 |
| Sep 30, 2020 |
-8,173.00 |
| Jun 30, 2020 |
503.00 |
| Jun 30, 2019 |
-25,294.00 |
| Dec 31, 2018 |
19,474.00 |
| Mar 31, 2018 |
12,170.00 |
| Dec 31, 2017 |
214.00 |
| Jun 30, 2017 |
-64,592.00 |
| Dec 31, 2016 |
122.00 |
| Jun 30, 2016 |
12,775.00 |
| Dec 31, 2015 |
-169.28 Bn |
